Natural antibodies: Protecting role of IgM in glioblastoma and brain tumours

Semwal, Shubham; Boukherroub, Rabah; Savvides, Savvas; Bouckaert, Julie

Type de document :

Compte-rendu et recension critique d'ouvrage

DOI :

10.2174/1381612827666210728103524

Titre :

Natural antibodies: Protecting role of IgM in glioblastoma and brain tumours

Auteur(s) :

Semwal, Shubham [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 [UGSF]
Boukherroub, Rabah [Auteur]

NanoBioInterfaces - IEMN [NBI - IEMN]
Institut d’Électronique, de Microélectronique et de Nanotechnologie - UMR 8520 [IEMN]
Savvides, Savvas [Auteur]
Bouckaert, Julie [Auteur]

Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 [UGSF]

Titre de la revue :

Current Pharmaceutical Design

Pagination :

4515-4529

Éditeur :

Bentham Science Publishers

Date de publication :

2021-07-28

ISSN :

1381-6128

Mot(s)-clé(s) en anglais :

IgM
Glioblastoma
Natural Antibodies
Immunotherapy
Microglia
ALK

Discipline(s) HAL :

Sciences du Vivant [q-bio]
Chimie/Chimie théorique et/ou physique

Résumé en anglais : [en]

Background: Glioblastoma is a grade IV astrocytoma with an average survival span for patients of 18 months after initial diagnosis and no standard treatment protocol. There is a need to look at novel approaches to target ...
Lire la suite >Background: Glioblastoma is a grade IV astrocytoma with an average survival span for patients of 18 months after initial diagnosis and no standard treatment protocol. There is a need to look at novel approaches to target glioblastoma.Objectives: This review intends to capture the role of immunoglobulin-M in cancer, more specifically in glioblastoma multiforme (GBM), and to compile the latest developments and immunological pathways relevant to glioblastomaMethods: Information on glioblastoma, cancer microenvironment, cancer therapeutics and how to improve the scenario was obtained from scientific literature databases such as Pubmed, Medline, Google Scholar, Science Direct, Springer, Wiley online library and some data was harvested from regulatory and compliance databases such as clinicaltrials.gov, FDA database, WHO Globocan.Results and Conclusions: Currently, only a limited number of therapies are approved for GBM, and no standard of care is in place in case of disease relapse, necessitating a possible broader perspective in looking at the disease and its underlying mechanisms.Lire moins >

Langue :

Anglais

Vulgarisation :

Non

Projet Européen :

Programme for EArly-stage Researchers in Lille

Collections :